Journal Article
. 2020 Jul;11(6).
doi: 10.1038/s41419-020-2690-y.

A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway

Shu Wang 1 Yingshi Zhang 1 Tianshu Ren 1 Qiong Wu 1 Hongyuan Lu 1 Xiaochun Qin 1 Yuyan Liu 1 Huaiwei Ding 2 Qingchun Zhao 3 
Affiliations
  • PMID: 32606352
  •     54 References

Abstract

Breast cancer is one of the most frequent cancers among women worldwide. However, there is still no effective therapeutic strategy for advanced breast cancer that has metastasized. Aberrant activation of the PI3K/AKT/mTOR pathway is an essential step for the growth of human breast cancers. In our previous study, we designed and synthesized DHW-208 (2,4-difluoro-N-(5-(4-((1-(2-hydroxyethyl)-1H-pyrazol-4-yl)amino)quinazolin-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide) as a novel pan-PI3K inhibitor. This study aimed to assess the therapeutic efficacy of DHW-208 in breast cancer and investigate its underlying mechanism. We found that DHW-208 inhibited the growth, proliferation, migration, and invasion of breast cancer cells. Moreover, DHW-208 induced breast cancer cell apoptosis via the mitochondrial pathway and induced G0/G1 cell-cycle arrest. In vitro results show that DHW-208 is a dual inhibitor of PI3K and mTOR, and suppress the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway. Consistent with the in vitro results, in vivo studies demonstrated that DHW-208 elicits an antitumor effect by inhibiting the PI3K/AKT/mTOR-signaling pathway with a high degree of safety in breast cancer. Above all, we report for the first time that DHW-208 suppressed the growth of human breast cancer cells by inhibiting the PI3K/AKT/mTOR-signaling pathway both in vivo and in vitro. Our study may provide evidence for the use of DHW-208 as an effective, novel therapeutic candidate for the treatment of human breast cancers in clinical trials.

Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.
Liyan Du, Xiaomei Li, +4 authors, Ailin Song.
Mol Med Rep, 2018 Mar 24; 17(5). PMID: 29568883    Free PMC article.
Licochalcone A inhibits PI3K/Akt/mTOR signaling pathway activation and promotes autophagy in breast cancer cells.
Lei Xue, Wei-Jie Zhang, Qing-Xia Fan, Liu-Xing Wang.
Oncol Lett, 2018 Feb 06; 15(2). PMID: 29399197    Free PMC article.
Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin.
S Ikeda, S Kishida, +3 authors, A Kikuchi.
EMBO J, 1998 Apr 18; 17(5). PMID: 9482734    Free PMC article.
Highly Cited.
Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
Wenlu Li, Qinsheng Sun, +4 authors, Yuyang Jiang.
Eur J Med Chem, 2017 Nov 07; 141. PMID: 29107429
The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2- Metastatic Breast Cancer: Biological Mechanisms and New Treatments.
Daniele Presti, Erica Quaquarini.
Cancers (Basel), 2019 Aug 28; 11(9). PMID: 31450618    Free PMC article.
Review.
Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway.
Yan Guo, Hui Chang, +4 authors, Wen-chao Liu.
Apoptosis, 2015 May 24; 20(8). PMID: 26002438
BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway.
Xueke Liu, Chunmei Xie, +12 authors, Xiaolong Tang.
Am J Transl Res, 2020 Jan 15; 11(12). PMID: 31934276    Free PMC article.
Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
Zongjuan Li, Xiangdong Xu, +14 authors, Lijuan Zou.
Cell Physiol Biochem, 2018 Mar 02; 45(5). PMID: 29495002
PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation.
Var Ruchi Sharma, Girish Kumar Gupta, +4 authors, Anil K Sharma.
Curr Pharm Des, 2016 Nov 17; 23(11). PMID: 27848885
Review.
Endotoxin modulates the capacity of CpG-activated liver myeloid DC to direct Th1-type responses.
Masanori Abe, Daisuke Tokita, Giorgio Raimondi, Angus W Thomson.
Eur J Immunol, 2006 Aug 19; 36(9). PMID: 16917958
ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future.
Brett Rozeboom, Nandini Dey, Pradip De.
Am J Cancer Res, 2020 Jan 09; 9(12). PMID: 31911865    Free PMC article.
Review.
Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3Kα in Non-Small Cell Lung Cancer.
Yanhua Fan, Huaiwei Ding, +4 authors, Sang Kook Lee.
Cancers (Basel), 2019 May 08; 11(5). PMID: 31060329    Free PMC article.
SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity.
Fan Yin, Fan Feng, +3 authors, Yu Cao.
Cell Death Dis, 2019 Sep 13; 10(9). PMID: 31511501    Free PMC article.
Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.
Neal Shah, Afroz S Mohammad, +9 authors, Paul R Lockman.
Pharmacol Res, 2018 Apr 01; 132. PMID: 29604436    Free PMC article.
Review.
Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer.
Qiang He, Shuyin Xue, +7 authors, Guosheng Ren.
Cancer Lett, 2019 Feb 12; 448. PMID: 30742942
Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway.
Jin Zhou, Yuan-Yuan Jiang, +2 authors, Li Zhang.
Cell Prolif, 2019 Dec 11; 53(2). PMID: 31820522    Free PMC article.
Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Kazuhiro Araki, Yasuo Miyoshi.
Breast Cancer, 2017 Nov 01; 25(4). PMID: 29086897
Review.
PI3K/Akt/mTOR inhibitors in breast cancer.
Joycelyn Jx Lee, Kiley Loh, Yoon-Sim Yap.
Cancer Biol Med, 2016 Jan 19; 12(4). PMID: 26779371    Free PMC article.
Highly Cited. Review.
Lanatoside C Induces G2/M Cell Cycle Arrest and Suppresses Cancer Cell Growth by Attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR Signaling Pathways.
Dhanasekhar Reddy, Ranjith Kumavath, Preetam Ghosh, Debmalya Barh.
Biomolecules, 2019 Dec 01; 9(12). PMID: 31783627    Free PMC article.
Cryptotanshinone Inhibites Bladder Cancer Cell Proliferation and Promotes Apoptosis via the PTEN/PI3K/AKT Pathway.
Yadong Liu, Fanlu Lin, +4 authors, Ruihua An.
J Cancer, 2020 Jan 04; 11(2). PMID: 31897244    Free PMC article.
Lupiwighteone induces caspase-dependent and -independent apoptosis on human breast cancer cells via inhibiting PI3K/Akt/mTOR pathway.
Yeong-Seon Won, Kwon-Il Seo.
Food Chem Toxicol, 2019 Oct 12; 135. PMID: 31604113
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Robert Roskoski.
Pharmacol Res, 2018 Dec 01; 139. PMID: 30500458
Highly Cited. Review.
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.
Arkaitz Carracedo, Li Ma, +12 authors, Pier Paolo Pandolfi.
J Clin Invest, 2008 Aug 30; 118(9). PMID: 18725988    Free PMC article.
Highly Cited.
PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Rui Zhao, Yinghan Song, +8 authors, Yong Zhou.
Cell Prolif, 2019 Feb 05; 52(3). PMID: 30714229    Free PMC article.
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Debasis Das, Jian Hong.
Eur J Med Chem, 2019 Mar 18; 170. PMID: 30878832
Review.
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.
Angel Guerrero-Zotano, Ingrid A Mayer, Carlos L Arteaga.
Cancer Metastasis Rev, 2016 Nov 30; 35(4). PMID: 27896521
Highly Cited. Review.
Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment.
Deniz Cansen Kahraman, Tamer Kahraman, Rengul Cetin-Atalay.
Mol Cancer Ther, 2019 Aug 24; 18(11). PMID: 31439713
Cullin7 enhances resistance to trastuzumab therapy in Her2 positive breast cancer via degrading IRS-1 and downregulating IGFBP-3 to activate the PI3K/AKT pathway.
Ni Qiu, Yu-Fang He, +13 authors, Hong-Sheng Li.
Cancer Lett, 2019 Aug 29; 464. PMID: 31461670
A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway.
Guang-Yong Li, Kyung Hee Jung, +6 authors, Soon-Sun Hong.
Cancer Lett, 2012 Oct 23; 329(1). PMID: 23085493
Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
Huai-Wei Ding, Cheng-Long Deng, +9 authors, Hong-Rui Song.
Eur J Med Chem, 2018 Feb 07; 146. PMID: 29407971
Properties of FDA-approved small molecule protein kinase inhibitors.
Robert Roskoski.
Pharmacol Res, 2019 Mar 17; 144. PMID: 30877063
Highly Cited. Review.
Autophagy inhibition enhances Matrine derivative MASM induced apoptosis in cancer cells via a mechanism involving reactive oxygen species-mediated PI3K/Akt/mTOR and Erk/p38 signaling.
Yuming Zou, Melika Sarem, +3 authors, V Prasad Shastri.
BMC Cancer, 2019 Oct 17; 19(1). PMID: 31615459    Free PMC article.
Inhibition of TPA‑induced metastatic potential by morin hydrate in MCF‑7 human breast cancer cells via the Akt/GSK‑3β/c‑Fos signaling pathway.
Kyu-Shik Lee, Gi Suk Nam, +2 authors, Kyung-Soo Nam.
Int J Oncol, 2020 Jan 16; 56(2). PMID: 31939617
Breast cancer statistics, 2019.
Carol E DeSantis, Jiemin Ma, +5 authors, Rebecca L Siegel.
CA Cancer J Clin, 2019 Oct 03; 69(6). PMID: 31577379
Highly Cited.
AKT and ERK dual inhibitors: The way forward?
Zhe Cao, Qianjin Liao, +3 authors, Deliang Cao.
Cancer Lett, 2019 May 28; 459. PMID: 31128213
Review.
GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer.
Jintao Lin, Tao Song, Cong Li, Weifeng Mao.
Biochim Biophys Acta Mol Cell Res, 2020 Jan 25; 1867(5). PMID: 31978503
Review.
MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents.
Bin Yang, Chunping Wang, +7 authors, Yinying Lu.
Cell Death Dis, 2019 Oct 16; 10(10). PMID: 31611551    Free PMC article.
Strophanthidin Attenuates MAPK, PI3K/AKT/mTOR, and Wnt/β-Catenin Signaling Pathways in Human Cancers.
Dhanasekhar Reddy, Preetam Ghosh, Ranjith Kumavath.
Front Oncol, 2020 Feb 06; 9. PMID: 32010609    Free PMC article.
Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
Joseph J Caumanns, Anne van Wijngaarden, +6 authors, Steven de Jong.
Cancer Lett, 2019 Jul 19; 461. PMID: 31319139
Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway.
Ruijuan Zhou, Hongjiu Chen, +3 authors, Leqin Xu.
BMC Complement Altern Med, 2018 Mar 11; 18(1). PMID: 29523109    Free PMC article.
Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer.
S-U Woo, T Sangai, +3 authors, F Meric-Bernstam.
Oncogenesis, 2017 Oct 11; 6(10). PMID: 28991258    Free PMC article.
An animal model of human cytomegalovirus infection.
L Gao, S Qian, +4 authors, S Zheng.
Transplant Proc, 2007 Dec 20; 39(10). PMID: 18089401
Advances in the researches on the biological activities and inhibitors of phosphatidylinositol 3-kinase.
Jian-Feng Tang, Qing Wen, +2 authors, Hai-Liang Zhu.
Anticancer Agents Med Chem, 2013 Oct 30; 14(5). PMID: 24164048
Review.
CLE-10 from Carpesium abrotanoides L. Suppresses the Growth of Human Breast Cancer Cells (MDA-MB-231) In Vitro by Inducing Apoptosis and Pro-Death Autophagy Via the PI3K/Akt/mTOR Signaling Pathway.
Li Tian, Fan Cheng, +3 authors, Jianfeng Chen.
Molecules, 2019 Mar 23; 24(6). PMID: 30897708    Free PMC article.
Aminophenols increase proliferation of thyroid tumor cells by inducing the transcription factor activity of estrogen receptor α.
Lin Wang, Ling Zhao, +4 authors, Zhaohui Lyu.
Biomed Pharmacother, 2018 Nov 07; 109. PMID: 30399599
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Znhit1 inhibits breast cancer by up-regulating PTEN to deactivate the PI3K/Akt/mTOR pathway.
Chunguo Cui, Sijie Li, Di Wu.
Life Sci, 2019 Apr 01; 224. PMID: 30928405
2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
Jingwen Xu, Mengting Han, +8 authors, Yingliang Wu.
Cancer Lett, 2016 Oct 30; 383(1). PMID: 27693458
A novel hydrogen sulfide-releasing donor, HA-ADT, suppresses the growth of human breast cancer cells through inhibiting the PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signaling pathways.
Qian Dong, Bo Yang, +10 authors, Shao-Feng Duan.
Cancer Lett, 2019 May 03; 455. PMID: 31042588
Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo.
Ling Wei, Yongzhi Lun, +6 authors, Chengbin Wang.
Pharmacol Res, 2019 Mar 14; 143. PMID: 30862605
Anti‑cancer effects of fisetin on mammary carcinoma cells via regulation of the PI3K/Akt/mTOR pathway: In vitro and in vivo studies.
Xu Sun, Xueman Ma, +9 authors, Xiaomin Wang.
Int J Mol Med, 2018 May 12; 42(2). PMID: 29749427    Free PMC article.
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.
Sauveur-Michel Maira, Frédéric Stauffer, +14 authors, Carlos García-Echeverría.
Mol Cancer Ther, 2008 Jul 09; 7(7). PMID: 18606717
Highly Cited.
MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway.
J Li, T You, J Jing.
Cell Prolif, 2014 Feb 13; 47(2). PMID: 24517182    Free PMC article.
Highly Cited.
Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.
M Brandão, R Caparica, D Eiger, E de Azambuja.
Ann Oncol, 2019 Dec 21; 30(Suppl_10). PMID: 31859350    Free PMC article.
Review.